Investor FAQs

Show all

Investor FAQs

We are a biopharmaceutical company focused on developing our robust pipeline of product candidates including fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including a joint development arrangement evaluating the potential of CNSA-001 in phenylketonuria (PKU), a rare genetic metabolic condition that can lead to neurological and behavioral impairment.

Retrophin was founded in February 2011 and became public by reverse merger in December 2012.
Retrophin’s fiscal year ends December 31.
Retrophin is traded on NASDAQ with a ticker symbol of RTRX.
Retrophin is incorporated in Delaware.
Retrophin’s CUISP number is 761299 10 6.
3721 Valley Centre Drive, Suite 200
San Diego, CA 92130
Steve Aselage, Chief Executive Officer
Neil McFarlane, Chief Operating Officer
Laura Clague, Chief Financial Officer
Elizabeth Reed, General Counsel and Corporate Secretary
William “Bill” Rote, PHD, SVP, Research and Development
Retrophin does not pay a dividend at this time.
Retrophin does not have a Dividend Reinvestment Plan at this time.
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219 Toll free (800) 937-5449
Direct (718) 921-8124 info@amstock.com
Contact the transfer agent.
To change your address, contact the transfer agent.
All publications are available on this Website.